These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 18190632)

  • 1. Use of androgen deprivation therapy for metastatic prostate cancer in older men.
    Keating NL; O'Malley AJ; McNaughton-Collins M; Oh WK; Smith MR
    BJU Int; 2008 May; 101(9):1077-83. PubMed ID: 18190632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
    Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
    J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
    Nguyen C; Lairson DR; Swartz MD; Du XL
    J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race and Time to Receipt of Androgen Deprivation Therapy Among Men With Metastatic Prostate Cancer.
    Cobran EK; Young HN; Chen RC; Chen X; Reeves J; Godley PA; Shah S
    J Natl Med Assoc; 2019 Jun; 111(3):246-255. PubMed ID: 30389146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
    Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
    World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
    Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
    Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
    Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
    Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Androgen deprivation for advanced prostate cancer].
    Heidenreich A; Pfister D; Ohlmann CH; Engelmann UH
    Urologe A; 2008 Mar; 47(3):270-83. PubMed ID: 18273599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ; Oestreich MC; Brown SJ; Gupta S; Konety BR; Dahm P; Kunath F
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013245. PubMed ID: 33314020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
    Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
    Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients With Prostate Cancer.
    Morgan KM; Riviere P; Nelson TJ; Guram K; Deshler LN; Sabater Minarim D; Duran EA; Banegas MP; Rose BS
    JAMA Netw Open; 2024 Jun; 7(6):e2415911. PubMed ID: 38857047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
    Warde P; Mason M; Ding K; Kirkbride P; Brundage M; Cowan R; Gospodarowicz M; Sanders K; Kostashuk E; Swanson G; Barber J; Hiltz A; Parmar MK; Sathya J; Anderson J; Hayter C; Hetherington J; Sydes MR; Parulekar W;
    Lancet; 2011 Dec; 378(9809):2104-11. PubMed ID: 22056152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer.
    Holmes L; Chan W; Jiang Z; Du XL
    Prostate Cancer Prostatic Dis; 2007; 10(4):388-95. PubMed ID: 17486111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
    Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
    Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
    Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
    Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
    Morgans AK; Smith MR; O'Malley AJ; Keating NL
    Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.